Treatment of Cytomegalovirus Encephalitis in Pregnancy
Cytomegalovirus encephalitis during pregnancy is a clinically significant situation requiring a structured, protocol-guided approach. The indications for treating CMV infection in a pregnant patient follow the same established criteria applied in other high-risk populations.
Clinical Scenario
This protocol addresses CMV encephalitis specifically in the setting of pregnancy. During pregnancy, indications for treatment of CMV infection are the same as for other people with HIV, making evidence-based evaluation and treatment selection essential.
Treatment Approach — Partial Overview
Management involves targeted antiviral therapy. A specific oral antiviral agent has been identified as the preferred choice for maternal CMV disease in this setting, selected on the basis of its tolerability profile, available safety data, and practical ease of use.
Complete agent selection, dosing regimen, and full clinical algorithm available in the structured protocol →
References
During pregnancy, indications for treatment of CMV infection are the same as for other people with HIV (AIII).
Valganciclovir is the preferred treatment for maternal CMV disease during pregnancy (BIII).
Based on limited data (case reports only), toxicity reports, and ease of use of the various drugs, valganciclovir is considered the best choice of treatment for maternal CMV disease requiring treatment during pregnancy (BIII).
View source ↗